Literature DB >> 17136862

Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

M Mikov1, J P Fawcett, K Kuhajda, S Kevresan.   

Abstract

The role of bile acids in pharmacotherapy is reviewed in this article. The therapeutic use of bile has been recognized since ancient times. Previously bile acids were the standard treatment for gallstones where chenodeoxycholic acid and ursodeoxycholic acid were effective in promoting the dissolution of cholesterol gallstones. Today their therapeutic role looks set to expand enormously. Bile acids as absorption promoters have the potential to aid intestinal, buccal, transdermal, ocular, nasal, rectal and pulmonary absorption of various drugs at concentrations that are non-toxic. Keto derivatives of cholic acid, such as 3a,7a,dihydroxy-12-keto-5alpha-cholic acid (sodium salt and methyl ester) are potential modifiers of blood-brain barrier transport and have been shown to promote quinine uptake, enhance the analgesic effect of morphine and prolong the sleeping time induced by pentobarbital. They have also been shown to be hypoglycaemic. Bile acids as therapeutic agents have the potential to produce beneficial effects in sexually transmitted diseases, primary biliary cirrhosis, primary sclerosing cholangitis, gallstones, digestive tract diseases, cystic fibrosis, cancer and diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17136862     DOI: 10.1007/BF03190714

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  84 in total

1.  Further studies on the effect of additives on the release of drug from hard gelatin capsules.

Authors:  J M Newton; G Rowley; J F Törnblom
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

2.  Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha-tocopherol dispersions.

Authors:  Mounir S Mesiha; Sulochana Ponnapula; Fotios Plakogiannis
Journal:  Int J Pharm       Date:  2002-12-05       Impact factor: 5.875

3.  New ultradeformable drug carriers for potential transdermal application of interleukin-2 and interferon-alpha: theoretic and practical aspects.

Authors:  C Hofer; R Hartung; R Göbel; P Deering; A Lehmer; J Breul
Journal:  World J Surg       Date:  2000-10       Impact factor: 3.352

Review 4.  PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.

Authors:  Andrew C Li; Christopher K Glass
Journal:  J Lipid Res       Date:  2004-10-16       Impact factor: 5.922

Review 5.  Medical management of common bile duct stones.

Authors:  A González-Koch; F Nervi
Journal:  World J Surg       Date:  1998-11       Impact factor: 3.352

6.  Effect of intraduodenal bile salt on pancreaticobiliary responses to bombesin and to cholecystokinin in humans.

Authors:  P W Thimister; W P Hopman; A Tangerman; G Rosenbusch; H L Willems; J B Jansen
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

7.  Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption.

Authors:  W G Hardison; S M Grundy
Journal:  Gastroenterology       Date:  1984-07       Impact factor: 22.682

8.  Effect of bile salt on amylase release from rat pancreatic acini.

Authors:  R D Duan; C Erlanson-Albertsson
Journal:  Scand J Gastroenterol       Date:  1985-12       Impact factor: 2.423

9.  3Alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate as blood-brain barrier permeator.

Authors:  Momir Mikov; Slavko Kevresan; Ksenija Kuhajda; Vida Jakovljević; Velibor Vasović
Journal:  Pol J Pharmacol       Date:  2004 May-Jun

10.  The ocular route for systemic insulin delivery in the albino rabbit.

Authors:  A Yamamoto; A M Luo; S Dodda-Kashi; V H Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

View more
  18 in total

1.  Effect of cholic acid and its keto derivatives on the analgesic action of lidocaine and associated biochemical parameters in rats.

Authors:  Mihalj Posa; Slavko Kevresan; Momir Mikov; Vera Cirin-Novta; Ksenija Kuhajda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Apr-Jun       Impact factor: 2.441

2.  Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells.

Authors:  Dokyoung Lee; Dongkyu Kim; Hyejung Mok; Ji Hoon Jeong; Donghoon Choi; Sun Hwa Kim
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

3.  Synthesis and evaluation of bile acid amides of [Formula: see text]-cyanostilbenes as anticancer agents.

Authors:  Devesh S Agarwal; Rajnish Prakash Singh; K Lohitesh; Prabhat N Jha; Rajdeep Chowdhury; Rajeev Sakhuja
Journal:  Mol Divers       Date:  2017-12-13       Impact factor: 2.943

Review 4.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 5.  The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.

Authors:  Maja Stojancevic; Karmen Stankov; Momir Mikov
Journal:  Can J Gastroenterol       Date:  2012-09       Impact factor: 3.522

6.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-28       Impact factor: 2.441

7.  Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats.

Authors:  Aleksandar Rasković; Momir Mikov; Ranko Skrbić; Vida Jakovljević; Velibor Vasović; Mihalj Posa; Ksenija Kuhajda; Slavko Kevresan; Zdenko Tomic; Djendji Siladji
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

8.  Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.

Authors:  Armin Mooranian; Rebecca Negrulj; Hesham S Al-Sallami; Zhongxiang Fang; Momir Mikov; Svetlana Golocorbin-Kon; Marc Fakhoury; Gerald F Watts; Vance Matthews; Frank Arfuso; Amanda Lambros; Hani Al-Salami
Journal:  AAPS PharmSciTech       Date:  2014-08-29       Impact factor: 3.246

9.  The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.

Authors:  Momir Mikov; Hani Al-Salami; Svetlana Golocorbin-Kon; Ranko Skrbic; Aleksandar Raskovic; J Paul Fawcett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

10.  Influence of Biotechnological Processes, Speed of Formulation Flow and Cellular Concurrent Stream-Integration on Insulin Production from β-cells as a Result of Co-Encapsulation with a Highly Lipophilic Bile Acid.

Authors:  Armin Mooranian; Rebecca Negrulj; Ryu Takechi; Emma Jamieson; Grant Morahan; Hani Al-Salami
Journal:  Cell Mol Bioeng       Date:  2017-10-03       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.